CSIMarket
 
Takeda Pharmaceutical Company Limited  (NYSE: TAK)
 
Price: $18.1550 $-0.05 -0.302%
Day's High: $18.329999923706055 Week Perf: -2.97 %
Day's Low: $ 18.14 30 Day Perf: 3.86 %
Volume (M): 570,548 52 Wk High: $ 18.90
Volume (M$): $ 0 52 Wk Avg: $16.30
Open: $18.34 52 Wk Low: $12.99



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 47,000
 Revenues (TTM) (Millions $) 29,184
 Net Income (TTM) (Millions $) 689
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1,279

Business Description


Takeda Pharmaceutical Company Limited is a renowned global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1781, it has a rich history of more than 230 years in the healthcare industry. Takeda operates with a mission to provide better health and brighter future for people worldwide through innovative and high-quality pharmaceutical products.

The company specializes in various therapeutic areas including oncology, gastroenterology, neuroscience, rare diseases, and vaccines. Takeda focuses on research and development (R&D) to discover and develop innovative medicines that address unmet medical needs and improve patient outcomes. They have a strong pipeline of promising drug candidates under development.

Takeda has a significant global presence, with operations in around 80 countries and regions. They collaborate with partners, healthcare professionals, and patient communities to deliver their products to patients in need across the globe. The company maintains a strong commitment to diversity and inclusion, environmental sustainability, and corporate social responsibility.

With a workforce of over 50,000 employees, Takeda continues to play a vital role in the pharmaceutical industry, constantly striving to improve healthcare and contribute to the well-being of people worldwide.


   Company Address: 1-1, Nihonbashi-Honcho 2-Chome Tokyo 103
   Company Phone Number: 3 3278-2306   Stock Exchange / Ticker: NYSE TAK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.56%    
ABT   -6.44%    
BMY   -5.78%    
JNJ   -3.22%    
MRK   -4.57%    
PFE   -4.74%    
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.09
Working Capital Ratio 0.56
Leverage Ratio (MRQ) 1.05
Total Debt to Equity 0.58
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.04

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 620,934
Net Income per Employee (TTM) 14,657
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.32

Profitability Ratios Current
Gross Margin (MRQ) 65.51 %
Operating Margin (MRQ) 7.48 %
Net Margin (MRQ) 2.36 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 38.23 %

Management Effectiveness Current
Return On Assets (TTM) 0.76 %
Return On Investment (TTM) 1.11 %
Return On Equity (TTM) 1.56 %
Dividend Yield -
Pay out Ratio (TTM) -



Takeda Pharmaceutical Limited's Segments
Sales of pharmaceutical products    98.13 % of total Revenue
Out-licensing and service income    1.87 % of total Revenue
Total Gastroenterology    29.62 % of total Revenue
ENTYVIO    19.95 % of total Revenue
GATTEX REVESTIVE    3.19 % of total Revenue
TAKECAB VOCINTI    2.85 % of total Revenue
PANTOLOC CONTROLOC    0.97 % of total Revenue
DEXILANT    0.84 % of total Revenue
EOHILIA    0.12 % of total Revenue
Others    5.19 % of total Revenue
Total Rare Diseases    16.43 % of total Revenue
TAKHZYRO    4.87 % of total Revenue
ADVATE    2.44 % of total Revenue
ELAPRASE    2.12 % of total Revenue
REPLAGAL    1.7 % of total Revenue
ADYNOVATE ADYNOVI    1.41 % of total Revenue
VPRIV    1.17 % of total Revenue
LIVTENCITY    0.72 % of total Revenue
ADZYNMA    0.15 % of total Revenue
Total PDT    22.54 % of total Revenue
Immunoglobulin    16.54 % of total Revenue
Albumin    3.09 % of total Revenue
Total Oncology    12.23 % of total Revenue
ADCETRIS    2.82 % of total Revenue
LEUPLIN ENANTONE    2.6 % of total Revenue
NINLARO    1.99 % of total Revenue
ICLUSIG    1.54 % of total Revenue
FRUZAQLA    1.05 % of total Revenue
ALUNBRIG    0.8 % of total Revenue
Total Vaccines    1.21 % of total Revenue
QDENGA    0.78 % of total Revenue
Total Neuroscience    12.35 % of total Revenue
VYVANSE ELVANSE    7.65 % of total Revenue
TRINTELLIX    2.74 % of total Revenue
ADDERALL XR    0.62 % of total Revenue
Total Other    5.62 % of total Revenue
AZILVA    0.26 % of total Revenue
FOSRENOL    0.17 % of total Revenue
Japan    1433.88 % of total Revenue
U S    8153.99 % of total Revenue
Europe and Canada    3615.87 % of total Revenue
Latin America    808.14 % of total Revenue
China    657.01 % of total Revenue
Asia excluding Japan China    340.57 % of total Revenue
Russia CIS    247.93 % of total Revenue
Other    441.51 % of total Revenue
Cencora Group Customer risk concentration net sales    12.59 % of total Revenue
McKesson Group Customer risk concentration net sales    12.93 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.